Charles Cohen

Charles M.
Cohen founded Synthesis Capital in 2007, where he worked as Principal from 2007 to 2012, Creative Biomolecules, Inc. in 1982, where he worked as Chief Executive Officer & Director from 1985 to 1995, Cellzome Ltd. in 2000, where he worked as Chairman, Aureon Biosciences, Inc. in 2001, where he worked as Director, Trident Pharmaceuticals, Inc. in 2006, where he worked as President & Chief Executive Officer from 2006 to 2011, and Prexa Pharmaceuticals, Inc. in 2006, where he worked as Chairman & Chief Executive Officer.
Dr. Cohen also currently works at Sirion Holdings, Inc., as Director.
Dr. Cohen also formerly worked at Ampla Pharmaceuticals, Inc., as President, Chief Executive Officer & Director, On Target Therapeutics, LLC, as Chief Executive Officer & Director from 2015 to 2017, Perform Biologics, Inc., as Chief Executive Officer & Director from 2015 to 2019, Cellzome AG, as Chairman-Supervisory Board from 2002 to 2012, Exelixis, Inc., as Independent Director from 1995 to 2022, Archemix Corp., as Director, Anesiva, Inc., as Director from 2005 to 2007, Anadys Pharmaceuticals, Inc., as Director from 2000 to 2005, ReVision Therapeutics, Inc., as Director, AlgoRx Pharmaceuticals, Inc., as Director, Advent International LP, as Partner, and Painewebber Group, Inc., as Advisor from 1998 to 2001.
Dr. Cohen received his undergraduate degree from State University of New York at Buffalo and doctorate degree from New York University School of Medicine.